Onsera Health

Onsera Health is a clinical-stage biotechnology company dedicated to developing innovative topical therapies for dermatological and neurological conditions, with a primary focus on chronic pruritus (itch). The company's lead program, ONS-101, is a topical small molecule inhibitor of Tropomyosin receptor kinase A (TrkA) designed to disrupt the nerve growth factor (NGF) signaling pathway. This pathway is a known driver of neurogenic inflammation and the sensation of itch in conditions such as atopic dermatitis. By utilizing a topical formulation, Onsera aims to provide targeted relief at the site of inflammation while avoiding the systemic side effects often associated with oral treatments. The company is led by a management team with extensive experience in the development of specialty pharmaceuticals.